ArticlePloS one2025
Single-cell transcriptomic analysis reveals the association of Ccl6+Ccr2+Arg1+ macrophages with renal interstitial fibrosis in AKI.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Pharmacological targeting of kidney fibrosis: druggable mechanisms, translational models, and emerging antifibrotic therapies.Clinical kidney journal · 2026Review
- The Lactate-lactylation circuitry in kidney fibrosis: cellular crosstalk from tubular metabolic reprogramming to macrophage effector functions.Seminars in immunopathology · 2026Review
- Synovial transcriptome analysis reveals ShenTong ZhuYu Tang alleviates osteoarthritis by targeting MMP-9 and immune microenvironment.Journal of orthopaedic surgery and research · 2026Article
- The chemokine network in triple-negative breast cancer: its role in immune microenvironment regulation, and prospects for targeted therapy.Frontiers in immunology · 2026Review
- Macrophage Plasticity and Regulatory Networks During the Transition from Inflammation to Fibrosis in the Kidney.Life (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcute kidney injury (AKI) is a major health burden with a high risk of progression to chronic kidney disease (CKD). Renal fibrosis is the ultimate outcome of CKD progression, with M2 macrophages playing a critical role by secreting pro-fibrotic factors. Chemokines can influence the progression of renal fibrosis by modulating macrophage polarization during the course of AKI.
methodsAn integrative analysis of single-cell transcriptomic data from kidneys of mice 7 days after AKI was performed to investigate ligand-receptor (LR) interactions between macrophages and to explore gene co-expression patterns during macrophage differentiation under AKI conditions. The AKI model was induced by unilateral ischemia-reperfusion injury (uIRI), and kidney samples were harvested at day 7. qPCR and WB were employed to measure the transcriptional levels of Ccl6, Ccr2, and M2 polarization markers in macrophages. Transwell assays were performed to evaluate the effect of Ccl6 on BMDMs migration. Cell proliferation was assessed using the Cell Counting Kit-8 (CCK-8) assay. Histological analysis was performed to assess the extent of kidney injury and fibrosis. Multiplex immunofluorescence analysis was conducted to assess the co-localization of Ccl6, Ccr2, and Arg1 expression.
resultsThrough integrated analysis of multiple single-cell transcriptomic datasets from AKI, we identified strong interactions between Ccl6 and Ccr2 in renal macrophages at 7 days post-AKI. Additionally, co-expression of Ccl6, Ccr2, and Arg1 was observed in renal macrophages, and the abundance of Ccl6+Ccr2+Arg1+ cells was positively correlated with the severity of renal interstitial fibrosis. Ccl6 promoted the migration and M2 polarization of bone marrow-derived macrophages (BMDMs). Inhibition of Ccr2 in AKI mice reduced the infiltration of Arg1+ macrophages and attenuated the progression of renal fibrosis.
conclusionTargeting the Ccl6/Ccr2 axis may attenuate fibrotic progression and offers potential therapeutic insights for preventing the transition from AKI to CKD, a possibility that warrants further validation through future functional experiments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.